Evaluation of the efficacy of bevacizumab combined with second-line chemotherapy in the treatment of metastatic colorectal cancer based on CT and serum tumor markers and quality of life
Objective:To evaluate the efficacy of bevacizumab combined with second-line chemotherapy in the treatment of metastatic colorectal cancer(CRC)based on CT,serum tumor markers and quality of life.Methods:Clinical data of 90 patients with metastatic CRC admitted to our hospital from January 2019 to January 2023 were retrospectively analyzed.According to different treatment regiments,they were divided into one line group(n=60,bevacizumab+oxaliplatin containing drug regimen),two line group(n=20,irinotecan containing drug regimen)and cross-line group(n=10,Irinotecan containing drug regimen).Bevacizumab plus oxaliplatin was given,and then bevacizumab plus irinotican was applied).The CT enhancement value,quality of life score,serum tumor marker level and clinical efficacy of the three groups were compared after treatment.Results:After treatment,CT enhancement value was significantly decreased in all 3 groups(P<0.05),SF-36 quality of life scale score was significantly increased(P<0.05),and CT enhancement value was one-line group<cross-line group<two-line group(P<0.05),SF-36 score was one-line group>cross-line group>two-line group(P<0.05).After treatment,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA12-5)and carbohydrate antigen 199(CA19-9)in 3 groups were significantly decreased(P<0.05),and the levels of markers were one-line group<cross-line group<two-line group(P<0.05).After treatment,there was no significant difference in objective response rate(ORR)and disease control rate(DCR)among 3 groups(P>0.05).Conclusion:Bevacizumab combined with first-line or second-line chemotherapy is effective in the treatment of metastatic CRC,but the use of bevacizumab in first-line treatment is more beneficial to reduce the CT enhancement value and serum tumor marker level of patients,and improve the quality of life,which is worthy of recommendation.
Metastatic colorectal cancerBevacizumabChemotherapy treatmentCT enhancement valueSerum tumor markersQuality of life
NETL
NSTL
万方数据
